

European Journal of Pharmacology 423 (2001) 143-147



Short communication

Direct evidence for the interaction of neurokinin A with the tachykinin NK₁ receptor in tissue

Andrew A. Bremer*, Morris F. Tansky, Meiye Wu, Norman D. Boyd, Susan E. Leeman

Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Box 388, 715 Albany Sreet, Boston, MA 02118, USA

Received 12 March 2001; received in revised form 30 May 2001; accepted 1 June 2001

Abstract

Neurokinin A (NKA) is a tachykinin peptide that binds with high affinity to the tachykinin NK_2 receptor. Recent homologous binding studies, however, have shown that neurokinin A is also a high-affinity ligand for the tachykinin NK_1 receptor. In this report, we demonstrate that a photoreactive neurokinin A analogue specifically labels the NK_1 receptor in rat submandibular gland membranes and show via bioassay that neurokinin A is a potent stimulator of salivary secretion. Through the use of specific non-peptide antagonists in both photolabeling and functional assays, we unequivocally demonstrate that neurokinin A can specifically interact with the NK_1 receptor in vivo and elicit NK_1 receptor-mediated physiological responses. © 2001 Published by Elsevier Science B.V.

Keywords: Neurokinin A; Tachykinin NK₁ receptor; Photoaffinity labeling; Bioassay

1. Introduction

The tachykinins comprise a family of bioactive neurotransmitter/neuromodulatory peptides (Maggio, 1988). Neurokinin A and substance P are two mammalian tachykinins in particular that have been extensively studied (Otsuka and Yoshioka, 1993). The tachykinin receptor with the highest affinity for neurokinin A has been termed the tachykinin NK₂ receptor, and the tachykinin receptor with the highest affinity for substance P has been termed the tachykinin NK₁ receptor (Maggi et al., 1993). Both of these receptors are hepta-helical integral membrane proteins and belong to the rhodopsin-type family of cell-surface G-protein coupled receptors (Nakanishi, 1991).

Initial heterologous binding assays suggested that neurokinin A is a weak-affinity ligand for the NK₁ receptor due to its low efficiency in displacing radiolabeled substance P binding to the NK₁ receptor (Ingi et al., 1991). However, recent homologous binding assays using radiolabeled neurokinin A have shown that neurokinin A, despite its weak ability to compete with substance P binding, is nevertheless a high-affinity ligand for the NK₁ receptor expressed in transfected cell lines (Hastrup and Schwartz,

E-mail address: abremer@bu.edu (A.A. Bremer).

1996). Previous results from our laboratory have also shown that photoactivatable derivatives of substance P (SP) and neurokinin A (NKA), ¹²⁵I-Bolton Hunter (BH)-[*p*-benzoylphenylalanine (Bpa)⁸]SP and ¹²⁵I-[Bpa⁷]NKA, respectively, each specifically and efficiently photolabel the rat NK₁ receptor when expressed in chinese hamster ovary (CHO) cells (Bremer et al., 2000).

Having demonstrated the usefulness of photoaffinity labeling for the direct biochemical characterization of the rat NK₁ receptor in transfected cell lines, we turned our attention to examining whether this same approach could be used to biochemically characterize the binding site(s) of neurokinin A in tissue. We decided to first study the target of neurokinin A binding in the rat submandibular gland since earlier studies reported that neurokinin A as well as N-terminally extended neurokinin A derivatives stimulated salivary secretion (Takeda and Krause, 1989). Both neurokinin A and substance P are found in the rat submandibular gland (Otsuka and Yoshioka, 1993), and binding sites in this tissue for both radiolabeled neurokinin A and radiolabeled substance P have been documented by autoradiography (Buck and Burcher, 1985). The biochemical nature of the binding protein for substance P in submandibular gland tissue has been extensively characterized in our laboratory and known to be the NK₁ receptor (Boyd et al., 1991); however, the biochemical nature of the binding protein for neurokinin A in this tissue has not been established. Since mRNA encoding the NK₂ receptor has

^{*} Corresponding author. Tel.: +1-617-638-4387; fax: +1-617-638-4329.

not been reported in the rat submandibular gland (Takeda and Krause, 1991), we hypothesized that the NK₁ receptor was the site of neurokinin A binding. In this report, we unequivocally confirm this hypothesis by demonstrating through photoaffinity labeling techniques, biochemical analysis, and bioassay that neurokinin A can directly and functionally interact with the NK₁ receptor in vivo.

2. Materials and methods

2.1. Materials

Purified substance P and neurokinin A were purchased from Sigma, and ¹²⁵I-Bolton Hunter (BH) reagent (*N*-succinimidyl-3[4-hydroxyphenyl]propionate) and ¹²⁵I (each with specific activities of 2200 Ci/mmol) were obtained from NEN Life Sciences. ¹²⁵I-BH-[Bpa⁸]SP and ¹²⁵I-iodohistidyl¹-[Bpa⁷]NKA (¹²⁵I-[Bpa⁷]NKA) were prepared in our laboratory as described previously (Boyd et al., 1991; Bremer et al., 2000).

2.2. Rat submandibular gland tissue preparation

Rapidly frozen submandibular gland tissue was obtained from adult Sprague–Dawley rats (Zivic–Miller Laboratories). Tissues were homogenized in TE buffer (50 mM Tris, 1 mM EDTA, 0.1 mM phenylmethylsulfonyl fluoride, pH 7.4) containing 30 μ g/ml bacitracin at 4 °C. Nuclear and cellular debris were removed by centrifugation at $500 \times g$ for 10 min, and membranes were obtained by centrifugation of the supernatant at $30,000 \times g$ for 30 min. Following resuspension in TE buffer and recentrifugation, the final membrane pellet was resuspended in 12%

sucrose-containing TE buffer, rapidly frozen in liquid nitrogen, and stored at -80 °C. Membrane protein concentration was determined using the bicinchoninic acid (BCA) method (Pierce).

2.3. Photoaffinity labeling of submandibular gland membranes and identification of photolabeled proteins

Rat submandibular gland membranes were prepared and photolabeled as described previously (Boyd et al., 1991). Membranes, containing 3–5 mg of protein/ml, were incubated in the dark with 0.5-1.0 nM ¹²⁵I-BH-[Bpa⁸]SP or 3.0-3.5 nM ¹²⁵I-[Bpa⁷]NKA for 1 h at room temperature in TME buffer (50 mM Tris, 10 mM MgCl₂, 1 mM EGTA, pH 7.4) supplemented with 30 μg/ml bacitracin. Competing peptides or non-peptide antagonists were added at the concentrations indicated. Following incubation, the samples were diluted 10-fold with ice-cold TME buffer and centrifuged at $38,000 \times g$ for 15 min at 4 °C. The pellets were resuspended in ice-cold TME buffer and recentrifuged twice. Membranes were then resuspended in ice-cold buffer at 1-2 mg of membrane protein/ml and irradiated at 365 nm by exposure to a 100-W long-wave UV lamp for 15 min at a distance of 6 cm. Following photolysis, any ligand that remained reversibly bound to the membranes was dissociated by incubation of the membranes in TME buffer for 30 min at room temperature in the presence of 10 µM 5'-guanylylimidodiphosphate (Gpp[NH]p). ¹²⁵I-BH-[Bpa⁸]SP- or ¹²⁵I-[Bpa⁷]NKA-labeled membranes were then solubilized in sample buffer (0.125 M Tris, 2% sodium dodecyl sulfate (SDS), 10% glycerol, 0.01% bromophenol blue, pH 6.8), heated at 55 °C for 10 min, and subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) as described by Laemmli (1970).




Fig. 1. Photolabeling of rat submandibular gland membranes with (A) 125 I-BH-[Bpa⁸]SP and (B) 125 I-[Bpa⁷]NKA. Rat submandibular gland membranes were equilibrated with each photoligand in the presence and absence of indicated competitors and exposed to UV light. The photolabeled proteins were subsequently analyzed by SDS-PAGE/autoradiography. Lanes 1 and 6: no competitor added. Lanes 2 and 7: 1 μ M substance P added. Lanes 3 and 8: 1 μ M neurokinin A added. Lanes 4 and 9: 1 μ M RP 67,580 added. Lanes 5 and 10: 1 μ M SR 48,968 added. Arrows denote the full-length (\sim 53 kDa) and truncated (\sim 46 kDa) versions of the rat NK₁ receptor.

2.4. Salivation bioassay

Female rats weighing 100–200 g were anesthetized with pentobarbital (45 mg/kg). After 10 min, test solutions of substance P (3 nmol/kg) or neurokinin A (30 nmol/kg) were injected via the tail vein. Saliva was collected from the mouth with a Pasteur pipette, put into tared microfuge tubes, and weighed. In rats pre-treated with either the non-peptide rat NK₁ receptor antagonist RP 67,580 (7,7-diphenyl-2-[1-imino-2-(2methoxyphenyl)ethyl]perhydroisoindol-4-one(3aR,7aR)) (Garret et al., 1991) or the non-peptide rat NK₂ receptor antagonist SR 48,968 ((S)-N-methyl-N-[4-(4-acetylamino-4-phenyl piperidino-z-(3,4-dichloro-phenyl)-butyl] benzamide) (Emonds-Alt et al., 1992), 5 mg/kg of the respective receptor antagonist dissolved in acidified saline was administered intraperitoneally 30 min prior to intravenous administration of substance P or neurokinin A.

3. Results


3.1. ^{125}I -[Bpa⁷]NKA specifically photolabels the NK₁ receptor in rat submandibular gland membranes

In a comparative analysis (Fig. 1, lanes 1 and 6), we show that the same diffuse photolabeling pattern is observed when submandibular gland membranes are photolabeled with ¹²⁵I-BH-[Bpa⁸]SP and ¹²⁵I-[Bpa⁷]NKA. Since we have previously shown using pharmacological, biochemical, and immunological methods that 125 I-BH-[Bpa⁸]SP specifically photolabels the full-length (~ 53 kDa) and C-terminal truncated versions (~46 kDa) of the glycosylated rat NK₁ receptor in rat submandibular gland membranes (Kage et al., 1993), these results demonstrate that ¹²⁵I-[Bpa⁷]NKA specifically photolabels both of the rat NK₁ receptor populations photolabeled by ¹²⁵I-BH-[Bpa⁸]SP. Pharmacological evidence of the specificity of the interactions of these two photoligands with the rat NK receptor is provided by results showing that the addition of 1 μM substance P (Fig. 1, lanes 2 and 7), 1 μM neurokinin A (Fig. 1, lanes 3 and 8), or 1 μ M RP 67,580 (a specific non-peptide rat NK₁ receptor antagonist) (Fig. 1, lanes 4 and 9) prevents photolabeling of the rat NK₁ receptor by both photoligands. In marked contrast, the addition of 1 µM SR 48,968 (a specific non-peptide rat NK₂ receptor antagonist) (Fig. 1, lanes 5 and 10) has no effect on the photolabeling of the rat NK₁ receptor by each photoreactive peptide.

3.2. Neurokinin A specifically stimulates NK_1 receptormediated salivation in the rat

To assess the functionality of the neurokinin A/NK_1 receptor interaction, a rat salivation bioassay similar to the one used to document the functionality of substance P in

stimulating salivation (Leeman and Hammerschlag, 1967) was used. As shown, neurokinin A is a potent stimulator of salivary secretion in rats (Fig. 2A, column 3), albeit a weaker stimulator of salivary secretion than substance P (Fig. 2A, column 1). Pharmacological evidence that each ligand stimulates salivation via a functional interaction with the NK₁ receptor is provided by data showing that both the substance P- and the neurokinin A-stimulated






Fig. 2. Pharmacological characterization of substance P- and neurokinin A-stimulated salivary secretion. (A) Inhibitory effects of RP 67,580 on substance P- and neurokinin A-stimulated salivary secretion. Rats (100-120 g) were injected with either substance P (3 nmol/kg) or neurokinin A (30 nmol/kg), and salivary secretion was measured for 2 min following injection of the peptide. Other rats were pre-treated with RP 67,580 (5 mg/kg) 30 min prior to the administration of substance P or neurokinin A, and salivary secretion was measured for 2 min following injection of peptide. Numbers in parentheses correspond to the number of rats in each test group. (B) Lack of an inhibitory effect of SR 48,968 on neurokinin A-stimulated salivary secretion. Rats (180-200 g) were injected with neurokinin A (30 nmol/kg) and salivary secretion was measured for 2 min following injection of peptide. Other rats were pre-treated with SR 48,968 (5 mg/kg) 30 min prior to the administration of neurokinin A, and salivary secretion was measured for 2 min following injection of peptide. Numbers in parentheses correspond to the number of rats in each test group.

salivation is inhibited by pre-treatment with the specific non-peptide rat NK_1 receptor antagonist RP 67,580 (Fig. 2A, columns 2 and 4). In marked contrast, pre-treatment with the specific non-peptide rat NK_2 receptor antagonist SR 48,968 has no demonstrable effect on neurokinin Astimulated salivation (Fig. 2B).

4. Discussion

In this report, we have used photoaffinity labeling as a method to biochemically characterize the specific target of neurokinin A binding in the rat submandibular gland. Although photoaffinity labeling is also an extremely valuable method for examining peptide/receptor interactions at the molecular level, these experiments demonstrate the power of this technique in biochemically characterizing the specific targets of peptide binding in tissue, information that cannot always be reliably obtained by conventional reversible binding assays.

In the present study, data from photolabeling assays performed in parallel with ¹²⁵I-BH-[Bpa⁸]SP and ¹²⁵I-[Bpa⁷]NKA show that the same proteins are photolabeled by each ligand in rat submandibular gland membranes. We can conclude that the proteins photolabeled by each ligand are the same based on (i) comparable molecular weight as determined by SDS-PAGE and (ii) comparable pharmacological characterization with the use of competitor peptides and non-peptide antagonists (Fig. 1). Bioassay data also show that neurokinin A specifically stimulates salivation in vivo through its functional interaction with the NK₁ receptor (Fig. 2). That neurokinin A is a somewhat less potent stimulator of salivation than substance P may be due to its relative lower affinity for the NK₁ receptor (Hastrup and Schwartz, 1996) or possible differences in signaling mechanisms (Sagan et al., 1996). However, the ability of a specific non-peptide rat NK₁ receptor antagonist but not a specific non-peptide rat NK2 receptor antagonist to inhibit both photolabeling and salivation demonstrates unequivocally that neurokinin A can specifically interact with the NK₁ receptor in the rat submandibular gland to elicit an NK₁ receptor-mediated physiological response.

Confirming that neurokinin A functionally interacts with the NK₁ receptor in vivo is critical in permitting the use of the ¹²⁵ I-[Bpa⁷]NKA photoligand as a probe in subsequent studies to biochemically characterize the target of neurokinin A binding in other tissues. The presence of neurokinin A and NK₂ receptor immunoreactivity has been documented in the spinal cord (Otsuka and Yoshioka, 1993; Zerari et al., 1998); but of interest to many investigators in the tachykinin field is the apparent discrepancy between the amount of neurokinin A present and the relative expression of its 'preferred' NK₂ receptor in several discrete regions of the brain. Autoradiographic data demonstrates the binding of radiolabeled neurokinin A derivatives to proteins in many of these specific brain

regions (Dam and Quirion, 1994), and based on the present data, the ¹²⁵I-[Bpa⁷]NKA photoprobe should be useful in future studies aimed at biochemically characterizing the binding site(s) of neurokinin A in these and other tissues.

That both substance P and neurokinin A can functionally interact with the NK₁ receptor may have physiological significance since both peptides arise from the same preprotachykinin A gene (Nawa et al., 1984) are frequently co-localized (Otsuka and Yoshioka, 1993), and potentially initiate different NK₁ receptor-mediated second-messenger signaling pathways (Sagan et al., 1996). The ability of these two peptides to functionally interact with the NK₁ receptor permits a more complex regulation of tachykinin-mediated events; moreover, defects involving this regulation may have significant pathophysiological sequelae (Kraneveld et al., 2000; Quartara and Maggi, 1998).

Acknowledgements

This work was supported by a grant from the National Institute of Health: NS 31346.

References

- Boyd, N.D., White, C.F., Cerpa, R., Kaiser, E.T., Leeman, S.E., 1991.
 Photoaffinity labeling the substance P receptor using a derivative of substance P containing p-benzoylphenylalanine. Biochemistry 30, 336–342.
- Bremer, A.A., Leeman, S.E., Boyd, N.D., 2000. The common C-terminal sequences of substance P and neurokinin A contact the same region of the NK-1 receptor. FEBS Lett. 486, 43–48.
- Buck, S.H., Burcher, E., 1985. The rat submaxillary gland contains predominantly P-type tachykinin binding sites. Peptides 6, 1079–1084.
- Dam, T.V., Quirion, R., 1994. Comparative distribution of receptor types in the mammalian brain. In: Buck, S.H. (Ed.), The Tachykinin Receptors. Humana Press, Totowa, NJ, pp. 101–123.
- Emonds-Alt, X., Vilain, P., Goulaouic, P., Proietto, V., Broeck, D.V., Advenier, C., Naline, E., Neliat, G., Fur, G.L., Breliere, J.C., 1992. A potent and selective non-peptide antagonist of the neurokinin A (NK₂) receptor. Life Sci. 50, 101–106.
- Garret, C., Carruette, A., Fardin, V., Moussaoui, S., Peyronel, J.-F., Blanchard, J.-C., Laduron, P.M., 1991. Pharmacological properties of a potent and selective nonpeptide substance P antagonist. Proc. Natl. Acad. Sci. U. S. A. 88, 10208–10212.
- Hastrup, H., Schwartz, T.W., 1996. Septide and neurokinin A are high-affinity ligands on the NK-1 receptor: evidence from homologous versus heterologous binding analysis. FEBS Lett. 399, 264–266.
- Ingi, T., Kitajima, Y., Minamitake, Y., Nakanishi, S., 1991. Characterization of ligand-binding properties and selectivities of three rat tachykinin receptors by transfection and functional expression of their cloned cDNAs in mammalian cells. J. Pharmacol. Exp. Ther. 259, 968–975.
- Kage, R., Leeman, S.E., Boyd, N.D., 1993. Biochemical characterization of two different forms of the substance P receptor in rat submaxillary gland. J. Neurochem. 60, 347–351.
- Kraneveld, A.D., James, D.E., de Vries, A., Nijkamp, F.P., 2000. Excitatory non-adrenergic-non-cholinergic neuropeptides: key players in asthma. Eur. J. Pharmacol. 405, 113–129.

- Laemmli, U.K., 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680–685.
- Leeman, S.E., Hammerschlag, R., 1967. Stimulation of salivary secretion by a factor extracted from hypothalamic tissue. Endocrinology 81, 803–810.
- Maggi, C.A., Patacchini, R., Rovero, P., Giachetti, A., 1993. Tachykinin receptors and tachykinin receptor antagonists. J. Auton. Pharmacol. 13, 23–93.
- Maggio, J.E., 1988. Tachykinins. Annu. Rev. Neurosci. 11, 13-28.
- Nakanishi, S., 1991. Mammalian tachykinin receptors. Annu. Rev. Neurosci. 14, 123–136.
- Nawa, H., Kotani, H., Nakanishi, S., 1984. Tissue-specific generation of two preprotachykinin mRNAs from one gene by alternative RNA splicing. Nature 312, 729–734.
- Otsuka, M., Yoshioka, K., 1993. Neurotransmitter functions of mammalian tachykinins. Physiol. Rev. 73, 229–308.

- Quartara, L., Maggi, C.A., 1998. The tachykinin NK₁ receptor: Part II. Distribution and pathophysiological roles. Neuropeptides 32, 1–49.
- Sagan, S., Chassaing, G., Pradier, L., Lavielle, S., 1996. Tachykinin peptides affect differently the second messenger pathways after binding to CHO-expressed human NK-1 receptors. J. Pharmacol. Exp. Ther. 276, 1039–1048.
- Takeda, Y., Krause, J.E., 1989. Neuropeptide K potently stimulates salivary gland secretion and potentiates substance P-induced salivation. Proc. Natl. Acad. Sci. U. S. A. 86, 392–396.
- Takeda, Y., Krause, J.E., 1991. Pharmacological and molecular biological studies on the diversity of rat tachykinin NK-2 receptor subtypes in rat CNS, duodenum, vas deferens, and urinary bladder. Ann. N. Y. Acad. Sci. 632, 479–482.
- Zerari, F., Karpitskiy, V., Descarries, L., Couture, R., 1998. Astroglial distribution of neurokinin-2 receptor immunoreactivity in the rat spinal cord. Neuroscience 84, 1233–1246.